Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma.

Cancer Science
Michinori OguraErik Vandendries

Abstract

Inotuzumab ozogamicin (CMC-544), a humanized anti-CD22 antibody conjugated to the potent cytotoxic antibiotic calicheamicin, targets the CD22 antigen expressed on the majority of B-cell non-Hodgkin lymphomas. This phase I study assessed the tolerability, safety, pharmacokinetics, and preliminary efficacy of inotuzumab ozogamicin administered intravenously in combination with rituximab in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Ten patients were administered rituximab 375 mg/m(2) followed by inotuzumab ozogamicin at the maximum tolerated dose (1.8 mg/m(2)). Treatment was repeated every 28 days up to eight cycles, or until occurrence of disease progression or intolerable toxicity. The safety profile was similar to that of inotuzumab ozogamicin monotherapy, with hematologic adverse events occurring most frequently. The most common grade three or higher adverse events were thrombocytopenia (70%), neutropenia (50%), leukopenia (30%), and lymphopenia (30%). The overall response rate was 80% (8/10; 95% CI, 44-98%). Drug exposure increased with successive doses, similar to the pharmacokinetic profiles observed in previous phase I monotherapy studies. Efficacy results suggested promising antitumor acti...Continue Reading

References

Aug 15, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P McLaughlinB K Dallaire
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonG P Canellos
Nov 30, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N L HarrisC D Bloomfield
Aug 30, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T A DavisR Levy
Aug 26, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·John P LeonardDavid M Goldenberg
Sep 25, 2004·Journal of Pharmaceutical Sciences·Evelyn D LoboJoseph P Balthasar
Dec 30, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·John F DiJosephNitin K Damle
Jan 7, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·John F DiJosephNitin K Damle
Mar 5, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Myron S CzuczmanFrancisco J Hernandez-Ilizaliturri
Mar 24, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anjali AdvaniLuis Fayad
Jan 18, 2011·Hematology·John P Leonard, Peter Martin
Feb 18, 2011·The British Journal of Radiology·A A O Plumb, G Murphy

❮ Previous
Next ❯

Citations

Oct 15, 2011·Cancer Research·David J FitzGeraldIra Pastan
Oct 13, 2012·Journal of Hematology & Oncology·Shundong CangDelong Liu
Aug 29, 2013·Future Oncology·Chan Y CheahJohn F Seymour
Mar 17, 2015·Expert Opinion on Biological Therapy·Maro OhanianSusan O'Brien
Apr 9, 2014·Expert Opinion on Investigational Drugs·Tadeusz Robak, Ewa Robak
Jul 4, 2012·Pharmacology & Therapeutics·Takumi KiwamotoBruce S Bochner
Jan 24, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C Y CheahM L Wang
Jul 22, 2015·Current Oncology Reports·Amitkumar Mehta, Andres Forero-Torres
Mar 20, 2013·Pharmacology & Therapeutics·Puja Sapra, Boris Shor
Feb 28, 2016·Immunology Letters·Swati SikariaMojtaba Akhtari
Aug 22, 2016·Current Treatment Options in Oncology·Deepa Jagadeesh, Mitchell R Smith
Feb 6, 2017·European Journal of Haematology·Swapna Thota, Anjali Advani
Apr 2, 2017·Trends in Biotechnology·Jie WangJian-Jiang Zhong
Dec 12, 2018·British Journal of Clinical Pharmacology·Jennifer E HibmaJoseph P Boni
Sep 23, 2014·American Journal of Therapeutics·Michael T Tees, Lubomir Sokol
Aug 10, 2017·Expert Opinion on Emerging Drugs·Anna Wolska-WasherTadeusz Robak
Jan 1, 2014·International Scholarly Research Notices·Monika PodhoreckaJohannes Pawlowski
Feb 11, 2020·The Journal of Clinical Investigation·Stephen M Ansell, Yi Lin
Oct 8, 2014·Experimental and Therapeutic Medicine·Cundong JiaJingping Bai
May 9, 2013·Oncotarget·Jonathan FeldAmit K Verma
May 8, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michinori OguraDavid MacDonald

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.